Given the mesenchymal origin of osteosarcoma and its well-characterized reliance on ECM remodeling and EMT for progression, coupled with our preliminary data indicating high HMCN1 expression and functional essentiality in bone cancer contexts, we selected this aggressive tumor type for subsequent experimental validation of HMCN1’s oncogenic role (16–18). The gene discussed is HMCN1; the disease is osteosarcoma.